Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.

BMC pulmonary medicine - 12 Nov 2019

Torrisi Sebastiano Emanuele, Kahn Nicolas, Wälscher Julia, Sarmand Nilab, Polke Markus, Lars Kehler, Eichinger Monika, Heussel Claus Peter, Palmucci Stefano, Sambataro Francesca Maria, Sambataro Gianluca, Sambataro Domenico, Vancheri Carlo, Kreuter Michael

Abstract excerpt

BACKGROUND: Fibrosing, non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung diseases (fILDs) are a heterogeneous group of diseases characterized by a different amount of inflammation and fibrosis. Therapy is currently based on corticosteroids and/or immunomodulators. However, response to these therapies is highly variable, sometimes without meaningful improvement, especially in more fibrosing forms....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Diseases, Interstitial

Share to Pulmonary Fibrosis

Share to Pyridones

Share to Tertiary Care Centers

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 31718637
DOI: 10.1186/s12890-019-0937-0
PMCID: PMC6852748

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.PMID 31718637Read ↗

Progressive fibrotic interstitial lung disease.Semantic proximity Read ↗

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis.Semantic proximity Read ↗

Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies.Semantic proximity Read ↗

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.Semantic proximity Read ↗

An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?Semantic proximity Read ↗

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).Semantic proximity Read ↗

A new perspective on idiopathic pulmonary fibrosis research: From multi-dimensional mechanistic exploration to advances in precision therapy.Semantic proximity Read ↗

Recent advances in understanding idiopathic pulmonary fibrosisSemantic proximity Read ↗

Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.Semantic proximity Read ↗

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary FibrosisSemantic proximity Read ↗

[How i treat a patient with idiopathic pulmonary fibrosis].Semantic proximity Read ↗

What's in a name? That which we call IPF, by any other name would act the same.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.